Published in:
Open Access
01-12-2011 | Meeting abstract
Selenium and the risk of cancer in BRCA1 carriers
Authors:
J Lubinski, K Jaworska, K Durda, A Jakubowska, T Huzarski, T Byrski, M Stawicka, J Gronwald, B Górski, W Wasowicz, E Kilar, M Szwiec, D Surdyka, E Marczyk, P Sun, SA Narod
Published in:
Hereditary Cancer in Clinical Practice
|
Special Issue 2/2011
Login to get access
Excerpt
It has not been established if dietary factors or nutritional supplements impact on the incidence of cancer in high-risk women. We randomised 1135 women with a BRCA1 mutation to 250 micrograms daily of elemental selenium as sodium selenite, or to placebo, in a double-blind trial. After a median follow-up period of 35 months (range 6 to 62 months), there were 60 incident cases of cancer diagnosed in the selenium-supplemented group, versus 45 cases in the placebo group (hazard ratio 1.4; 95% CI: 0.9 to 2.0). Selenium supplementation was not associated with a reduction in the risk of primary breast cancer (hazard ratio 1.3; 95% CI: 0.7 to 2.5), of contralateral breast cancer (hazard ratio 1.5; 95% CI: 0.7 to 3.2), or of ovarian cancer (hazard ratio 1.3; 95% CI: 0.6 to 2.7). The results of this study do not support the recommendation that selenium supplementation should be offered to BRCA1 carriers for chemoprevention. …
